clinic
microbiolog
laboratori
focu
choos
new
test
often
perform
turnaround
time
labor
need
review
examin
avail
rapid
multiplex
test
differ
perspect
patient
consid
whether
publish
evid
support
notion
use
rapid
ondemand
test
oppos
batch
test
lead
better
patient
outcom
whether
broad
syndromebas
multiplex
panel
translat
better
patient
care
narrow
monoplex
duplex
assay
final
examin
synergi
clinic
microbiolog
antimicrobi
stewardship
program
necessari
ensur
rapid
test
implement
impact
patient
design
support
cmn
raison
antimicrobi
stewardship
program
asp
state
succinctli
infecti
diseas
societi
america
idsa
earli
guidanc
document
subject
optim
clinic
outcom
minim
unintend
consequ
antimicrobi
use
includ
toxic
select
pathogen
organ
emerg
resist
asp
intervent
effect
recent
systemat
review
publish
cochran
collabor
affirm
posit
impact
empir
treatment
adher
publish
guidelin
deescal
antimicrobi
treatment
switch
intraven
oral
therapeut
drug
monitor
use
restrict
antimicrobi
list
clinic
outcom
hospit
cost
clinic
microbiolog
laboratori
critic
partner
asp
quest
optim
antimicrobi
util
patient
outcom
reduc
hospit
cost
importantli
emerg
rapid
userfriendli
multiplex
assay
great
potenti
facilit
earlier
asp
intervent
howev
impact
rapid
diagnost
test
rdt
patient
outcom
clearer
assay
specimen
type
other
even
less
clear
optim
collabor
laboratori
asp
maxim
impact
bedsid
review
publish
data
relat
clinic
outcom
attribut
use
current
rdt
detect
pathogen
patient
bloodstream
infect
respiratori
infect
neurolog
infect
case
consid
follow
need
molecular
test
would
rapid
ondemand
test
worthwhil
patient
would
batch
test
suffic
final
evid
support
use
broad
syndrom
multiplex
test
narrow
monoplex
duplex
assay
suffic
effect
asp
intervent
includ
implement
rdt
categor
two
group
process
measur
outcom
measur
process
measur
includ
durat
antimicrobi
therapi
time
antimicrobi
optim
eg
escal
narrowspectrum
antimicrobi
regimen
broaden
deescal
involv
revers
exampl
outcom
measur
includ
length
stay
lo
clinic
cure
eg
clearanc
bloodstream
infect
blood
cultur
incid
mortal
readmiss
advers
drug
reaction
hospit
cost
also
consid
outcom
measur
process
measur
outcom
measur
meaning
assess
impact
asp
intervent
patient
cost
bloodstream
infect
bsi
complic
associ
consider
morbid
mortal
wide
spectrum
organ
bsi
attribut
coupl
urgenc
associ
bsi
diagnosi
make
rapid
highli
sensit
multiplex
assay
attract
purpos
surprisingli
impact
rdt
patient
care
outcom
comprehens
studi
posit
blood
cultur
goal
earli
provis
organ
identif
antimicrobi
suscept
statu
earlier
optim
discontinu
antimicrobi
turn
may
translat
shorter
lo
reduc
mortal
decreas
hospit
cost
addit
filmarray
bcid
abil
detect
limit
group
antimicrobi
resist
determin
includ
meca
vana
blakpc
verigen
bcgn
also
detect
extendedspectrum
determin
blactxm
carbapenemas
determin
blandm
blaimp
blavim
genmark
diagnost
carlsbad
ca
recent
announc
ce
mark
eplex
blood
cultur
identif
gramposit
gramneg
panel
addit
recent
fdaclear
acceler
pheno
assay
acceler
diagnost
tucson
az
use
timelaps
microscopi
imag
analysi
report
antimicrobi
suscept
test
data
predefin
panel
drug
isol
blood
cultur
within
hour
variou
systemat
review
literatur
review
commentari
examin
whether
rapid
test
posit
blood
cultur
improv
patient
outcom
part
updat
guidelin
implement
asp
idsa
societi
healthcar
epidemiolog
shea
perform
literatur
review
focus
question
cite
data
base
implement
filmarray
bcid
malditof
ms
pna
fish
assay
xpert
mrsasa
bc
unavail
bd
geneohm
staphsr
assay
author
report
statist
signific
reduct
time
initi
appropri
antibiot
therapi
rate
recurr
bacteremia
lo
mortal
hospit
cost
rdt
posit
blood
cultur
coupl
asp
intervent
result
recommend
support
use
rdt
posit
blood
cultur
combin
asp
one
studi
deserv
specif
mention
banerje
colleagu
publish
nonblind
random
control
trial
patient
stratifi
three
arm
standard
blood
cultur
process
n
filmarray
bcid
templat
report
n
bcid
templat
report
plu
asp
intervent
form
realtim
audit
feedback
n
studi
adequ
power
show
differ
lo
mortal
hospit
cost
found
time
gram
stain
report
appropri
antimicrobi
deescal
escal
shortest
bcid
plu
asp
intervent
arm
banerje
et
al
therefor
provid
much
need
highqual
evid
document
increment
addit
benefit
coupl
rdt
asp
intervent
posit
blood
cultur
prior
emerg
wide
avail
rapid
molecular
assay
rapid
antigen
detect
test
influenza
viru
respiratori
syncyti
viru
direct
fluoresc
antibodi
test
viral
cultur
laboratorydevelop
molecular
test
ldt
use
detect
respiratori
virus
poor
sensit
rapid
antigen
test
direct
fluorescentantibodi
assay
dfa
viral
cultur
favor
use
molecular
test
howev
ldt
time
often
highli
sensit
specif
technic
skill
requir
implement
ldt
panel
difficult
achiev
mani
laboratori
labor
requir
necessit
batch
test
today
mani
laboratori
test
larg
given
way
rapid
autom
respiratori
pathogen
panel
test
perform
demand
test
includ
filmarray
respiratori
panel
durham
nc
viral
target
plu
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
verigen
rp
plu
rp
flex
luminex
austin
tx
viral
target
plu
b
pertussi
bordetella
parapertussisbordetella
bronchiseptica
bordetella
holmesii
variou
xpert
flursv
assay
cepheid
sunnyval
ca
simplexa
flursa
assay
focu
diagnost
cypress
ca
like
rdt
posit
blood
cultur
use
rapid
test
respiratori
ill
provid
opportun
optim
antimicrobi
administr
respiratori
viru
detect
ill
attribut
unnecessari
antibiot
mitig
discontinu
earli
case
involv
influenza
ab
rdt
may
expedit
treatment
antivir
eg
oseltamivir
potenti
reduc
durat
ill
although
impact
prevent
clinic
complic
remain
unclear
addit
uncertain
detect
respiratori
virus
influenza
viru
eg
parainfluenza
viru
respiratori
syncyti
viru
metapneumoviru
coronavirus
adenoviru
rhinoviru
use
molecular
test
panelbas
assay
rapid
batch
format
translat
benefit
patient
level
antivir
routin
use
treat
virus
deriv
clinic
benefit
rapid
test
clinic
team
would
need
feel
degre
reassur
posit
result
expedit
discontinu
antimicrobi
discharg
hospit
may
challeng
particularli
sick
patient
medic
literatur
data
support
use
current
rdt
respiratori
pathogen
detect
sparser
blood
cultur
rappo
colleagu
use
retrospect
quasiexperiment
design
compar
outcom
patient
posit
viral
studi
respiratori
viru
season
prior
implement
nasopharyng
test
n
filmarray
rp
biofir
salt
lake
citi
ut
season
assay
implement
n
preimplement
varieti
respiratori
viral
test
offer
includ
rapid
antigen
test
luminex
xtag
respiratori
viral
panel
luminex
austin
tx
dfa
viral
cultur
nasopharyng
swab
case
bronchoalveolar
lavag
specimen
follow
statist
adjust
potenti
confound
includ
age
immun
statu
asthma
diagnosi
admiss
intens
care
unit
multivari
analysi
among
patient
diagnos
influenza
lo
durat
antimicrobi
administr
number
chest
radiograph
perform
reduc
implement
filmarray
rp
phenomenon
observ
patient
respiratori
virus
influenza
viru
detect
studi
ultim
suggest
rapid
diagnosi
influenza
viru
infect
may
posit
impact
patient
outcom
rapid
detect
respiratori
virus
may
lead
similar
benefit
may
call
question
need
panel
test
broad
rang
respiratori
pathogen
roger
colleagu
report
lack
impact
lo
possibl
reduct
durat
antibiot
use
implement
filmarray
rp
pediatr
popul
use
similar
retrospect
quasiexperiment
design
clinic
outcom
respiratori
viral
season
prior
implement
filmarray
rp
n
compar
season
rp
implement
n
prior
rp
multiplex
ldt
pcr
assay
detect
viral
target
perform
daili
day
per
week
respiratori
viral
test
univari
analysi
show
mean
reduct
antimicrobi
day
day
statist
signific
chang
lo
follow
implement
filmarray
rp
report
rp
implement
reduc
lo
patient
posit
result
filmarray
rp
studi
suggest
switch
batch
pcrbase
respiratori
viral
panel
test
broader
rapid
respiratori
pathogen
panel
test
may
robustli
impact
patient
care
outcom
notabl
preval
influenza
viru
treatabl
viru
cohort
perhap
sever
respiratori
infect
evenli
match
preand
postintervent
group
therefor
bia
may
introduc
could
affect
studi
conclus
final
nonblind
studi
brendish
colleagu
compar
outcom
patient
random
filmarray
rp
perform
pointofcar
format
patient
assign
routin
care
control
control
group
clinic
team
determin
test
need
pursu
viral
studi
request
pcr
assay
includ
nine
viral
target
perform
central
laboratori
batch
fashion
follow
multivari
adjust
varieti
possibl
confound
variabl
differ
proport
patient
start
antimicrobi
durat
antimicrobi
use
isol
day
two
group
howev
mean
reduct
hospit
stay
confid
interv
day
p
note
rp
group
test
posit
influenza
ab
viru
posit
control
group
control
underw
test
respiratori
virus
studi
rappo
et
al
test
control
group
involv
routin
clinic
care
judgment
respons
clinic
team
difficult
gener
set
guidelin
implement
asp
idsa
shea
recommend
rapid
viral
test
pursu
respiratori
pathogen
effort
reduc
use
inappropri
antibiot
author
acknowledg
recommend
weak
base
lowqual
evid
assess
clinic
impact
implement
rapid
respiratori
test
therefor
appear
ongo
emerg
area
research
import
note
none
studi
describ
asp
integr
care
studi
patient
need
better
defin
optim
role
asp
implement
rdt
respiratori
infect
role
context
still
unclear
final
studi
focu
larg
diagnosi
communityacquir
respiratori
viral
infect
immunocompet
patient
optim
role
rdt
detect
nosocomi
hospitalacquir
viral
infect
immunocompromis
patient
would
also
benefit
investig
three
rapid
assay
fda
clear
molecular
detect
pathogen
cerebrospin
fluid
csf
infect
central
nervou
system
repres
concern
condit
encount
clinic
medicin
mortal
almost
certain
without
treatment
increas
morbid
mortal
associ
delay
therapi
hsv
enceph
bacteri
mening
idsa
recommend
acyclovir
administ
patient
present
enceph
broadspectrum
antibiot
initi
suspect
case
bacteri
mening
without
wait
diagnost
test
use
posit
blood
cultur
manag
enceph
mening
rdt
facilit
optim
antimicrobi
alreadi
start
opportun
optim
antimicrobi
administr
implement
assay
clearest
enterovirus
detect
correl
clinic
pictur
viral
mening
csf
sampl
rapidli
test
posit
enteroviru
patient
asept
mening
may
reassur
clinic
team
lead
expedit
discontinu
antibiot
acyclovir
patient
appear
well
similarli
hsv
mening
common
primari
genit
hsv
infect
earli
detect
could
lead
discontinu
antibiot
continu
acyclovir
convers
noncrit
patient
mening
neg
result
may
prompt
discuss
discontinu
nephrotox
neurotox
antivir
worth
note
patient
enceph
sensit
hsv
pcr
vari
particularli
earli
cours
ill
context
clinician
may
reluct
alter
acyclovir
therapi
without
repeatedli
neg
test
result
clinician
action
base
detect
bacteri
target
complex
clinic
team
may
reluct
adjust
antimicrobi
convent
cultur
antimicrobi
suscept
test
result
avail
particularli
patient
pediatr
fulmin
mening
hand
antimicrobi
suscept
h
influenza
l
monocytogen
n
meningitidi
agalactia
tend
rel
predict
detect
organ
may
allow
degre
optim
broadspectrum
antimicrobi
regimen
typic
start
empir
bacteri
mening
suspect
immunocompet
patient
clinic
impact
implement
molecular
test
diagnosi
mening
enceph
without
controversi
given
poor
sensit
histor
viral
cultur
howev
data
support
benefit
molecular
rdt
case
scarc
use
retrospect
quasiexperiment
studi
design
van
colleagu
recent
describ
effect
switch
realstar
alphaherpesviru
pcr
kit
multiplex
pcr
ldt
detect
varicella
zoster
viru
altona
diagnost
hamburg
germani
perform
per
day
day
per
week
simplexa
hsv
direct
assay
perform
demand
hour
per
day
day
per
week
studi
report
posit
result
among
patient
suspect
mening
andor
enceph
test
prior
rapid
test
patient
test
postimplement
studi
report
decreas
median
durat
acyclovir
therapi
hour
hour
author
felt
given
evid
renal
toxic
neurotox
typic
occur
within
first
hour
intraven
acyclovir
administr
reduct
acyclovir
use
associ
rapid
test
potenti
clinic
impact
posit
impact
batch
enteroviru
pcr
ldt
curtail
unnecessari
antibiot
day
lo
also
well
document
medic
literatur
data
demonstr
increment
benefit
rapid
ondemand
provis
enteroviru
statu
pcr
limit
small
singlecent
studi
use
quasiexperiment
design
regard
bacteri
detect
spinal
fluid
filmarray
meningitisenceph
assay
durham
nc
first
fdaclear
molecular
assay
detect
panel
bacteri
target
leber
et
al
report
assay
detect
h
influenza
pneumonia
csf
cultureneg
case
confirm
use
anoth
arbit
pcr
assay
dien
bard
colleagu
report
case
h
influenza
l
monocytogen
infect
note
clinic
trial
leber
et
al
also
report
falseposit
result
pneumonia
agalactia
e
coli
falseneg
result
agalactia
other
review
result
remark
institut
use
filmarray
may
wish
consid
implement
clinician
counsel
clinic
laboratori
andor
asp
ensur
posit
neg
result
interpret
appropri
addit
clinic
outcom
equal
import
measur
qualiti
care
patient
satisfact
may
also
independ
determin
patient
outcom
word
patient
happi
care
clinic
outcom
may
enhanc
driver
patient
satisfact
complex
varieti
differ
measur
tool
attempt
incorpor
key
element
data
deriv
feder
administ
hospit
consum
assess
healthcar
provid
system
survey
suggest
patient
satisfact
discharg
plan
may
associ
lower
hospit
readmiss
rate
time
accur
determin
agent
respons
infecti
condit
great
potenti
enhanc
clinic
team
abil
formul
ideal
discharg
plan
counsel
patient
clinic
cours
discharg
howev
need
evalu
posit
impact
rapid
test
would
need
weigh
cost
might
incur
patient
test
test
choos
manag
bsi
appear
suffici
evid
support
use
rapid
multiplex
test
tightli
coupl
asp
intervent
patient
respiratori
ill
howev
appear
compel
publish
evid
support
assert
multiplex
onesizefitsal
panel
whether
rapid
use
interestingli
least
one
manufactur
attempt
offer
flexibl
use
respiratori
panel
final
patient
mening
enceph
molecular
technolog
greatli
enhanc
abil
detect
respons
agent
appear
suffici
evid
assert
rapid
panel
duplex
test
improv
patient
care
outcom
other
state
previous
need
highqual
adequ
power
studi
determin
impact
avail
assay
health
care
process
patient
outcom
final
specif
patient
popul
eg
children
versu
adult
immunocompromis
versu
immunocompet
individu
need
consid
integr
decis
process
